StocksFundsScreenerSectorsWatchlists
UTMD

UTMD - Utah Medical Products Inc Stock Price, Fair Value and News

70.18USD0.00 (0.00%)Delayed as of 28 Mar 2024, 10:55 am ET

Market Summary

UTMD
USD70.180.00
Delayedas of 28 Mar 2024, 10:55 am
0.00%

UTMD Stock Price

View Fullscreen

UTMD RSI Chart

UTMD Valuation

Market Cap

248.9M

Price/Earnings (Trailing)

14.72

Price/Sales (Trailing)

4.96

EV/EBITDA

7.53

Price/Free Cashflow

11.5

UTMD Price/Sales (Trailing)

UTMD Profitability

EBT Margin

40.00%

Return on Equity

13.17%

Return on Assets

12.48%

Free Cashflow Yield

8.69%

UTMD Fundamentals

UTMD Revenue

Revenue (TTM)

50.2M

Rev. Growth (Yr)

-9.15%

Rev. Growth (Qtr)

-1.38%

UTMD Earnings

Earnings (TTM)

16.9M

Earnings Growth (Yr)

-8.06%

Earnings Growth (Qtr)

-6.31%

Breaking Down UTMD Revenue

52 Week Range

70.18100.59
(Low)(High)

Last 7 days

-1.0%

Last 30 days

-5.3%

Last 90 days

-19.6%

Trailing 12 Months

-22.6%

How does UTMD drawdown profile look like?

UTMD Financial Health

Current Ratio

22.56

UTMD Investor Care

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

4.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202352.5M51.9M51.5M50.2M
202250.4M51.2M51.6M52.3M
202142.2M46.1M48.1M49.1M
202047.1M44.0M42.0M42.2M
201941.8M42.7M44.8M46.9M
201842.0M42.2M42.4M42.0M
201739.3M39.6M40.1M41.4M
201640.2M40.3M40.0M39.3M
201541.7M41.6M40.8M40.2M
201439.9M40.4M41.1M41.3M
201340.7M40.7M40.2M40.5M
201242.3M41.9M41.6M41.6M
201125.5M29.6M34.2M37.9M
2010025.7M25.4M25.1M
200900025.9M

Tracking the Latest Insider Buys and Sells of Utah Medical Products Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 15, 2023
koopman brian
gifted
-5,658
94.31
-60.00
principal financial officer
May 18, 2023
richins paul o
sold
-65,429
93.47
-700
-
Mar 17, 2023
richins paul o
gifted
-13,875
92.5
-150
-
Feb 08, 2023
payne barbara a
gifted
-44,998
89.9974
-500
-
Dec 06, 2022
koopman brian
acquired
37,320
74.64
500
principal financial officer
Dec 06, 2022
koopman brian
sold (taxes)
-37,288
101
-366
principal financial officer
Nov 18, 2022
richins paul o
sold
-40,773
90.81
-449
-
Nov 17, 2022
richins paul o
sold
-14,490
90.00
-161
-
Nov 11, 2022
richins paul o
sold
-3,700
92.5
-40.00
-
Oct 31, 2022
koopman brian
gifted
-5,781
88.94
-65.00
principal financial officer

1–10 of 50

Which funds bought or sold UTMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
unchanged
-
-577
27,287
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.53
-81,949
14,379,600
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
68.53
2,290,990
5,813,200
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.35
-3,553
143,679
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-8.26
-210,000
1,853,000
-%
Feb 15, 2024
MERCER GLOBAL ADVISORS INC /ADV
reduced
-0.23
-8,000
370,000
-%
Feb 15, 2024
Legal & General Group Plc
added
30.02
11,117
51,795
-%
Feb 15, 2024
BARCLAYS PLC
added
626
344,000
401,000
-%
Feb 14, 2024
LAZARD ASSET MANAGEMENT LLC
added
493
117,000
141,000
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-29.89
-288,562
632,240
-%

1–10 of 49

Are Funds Buying or Selling UTMD?

Are funds buying UTMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own UTMD
No. of Funds

Unveiling Utah Medical Products Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
7.4%
269,166
SC 13G/A
Feb 13, 2024
renaissance technologies llc
5.64%
204,614
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
5.6%
204,421
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
9.4%
341,916
SC 13G
Feb 13, 2023
renaissance technologies llc
5.81%
210,614
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
4.62%
167,690
SC 13G/A
Feb 01, 2023
blackrock inc.
5.7%
205,514
SC 13G/A
Jun 10, 2022
price t rowe associates inc /md/
10.0%
365,212
SC 13G/A

Recent SEC filings of Utah Medical Products Inc

View All Filings
Date Filed Form Type Document
Mar 26, 2024
10-K
Annual Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 30, 2024
8-K
Current Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Dec 26, 2023
4
Insider Trading

What is the Fair Value of UTMD?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Utah Medical Products Inc News

Latest updates
Seeking Alpha • 22 Mar 2024 • 12:54 am
Defense World • 07 Mar 2024 • 07:43 am
Yahoo Finance • 30 Jan 2024 • 08:00 am
GlobeNewswire • 30 Jan 2024 • 08:00 am
Quartz • 30 Jan 2024 • 08:00 am
StockNews.com • 10 months ago

Utah Medical Products Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-1.4%12.0013.0013.0013.0014.0013.0013.0012.0013.0013.0013.0011.0012.0010.009.0011.0012.0012.0012.0011.0010.00
Gross Profit-3.5%7.007.008.008.008.008.008.008.008.008.008.007.007.006.005.007.008.007.008.007.006.00
Operating Expenses-100.0%-3.003.003.00-3.003.003.00-3.003.003.00-3.003.003.00-3.003.003.00-
  S&GA Expenses-100.0%-3.003.003.00-7.273.003.003.00-7.253.003.003.00-6.933.003.003.00-6.603.003.003.00-3.72
  R&D Expenses5.4%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EBITDA Margin-0.3%0.41*0.41*0.42*0.42*0.41*0.41*0.40*0.40*0.40*0.39*0.38*0.34*0.35*0.36*-------
Income Taxes-13.6%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.001.001.001.001.00
Earnings Before Taxes4.9%5.005.005.005.006.005.005.005.005.005.005.004.004.004.002.004.005.004.005.004.004.00
EBT Margin-0.4%0.40*0.40*0.41*0.40*0.40*0.39*0.39*0.39*0.39*0.38*0.36*0.33*0.33*0.34*-------
Net Income-100.0%-4.004.004.005.004.004.004.004.004.003.003.003.003.001.003.004.004.004.003.003.00
Net Income Margin2.5%0.34*0.33*0.33*0.33*0.32*0.31*0.31*0.30*0.30*0.29*0.28*0.25*0.26*0.28*-------
Free Cashflow6.2%5.005.005.007.006.005.005.005.005.006.004.006.006.005.00-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.2%135131130128124118116120116120117114112107104103110104103105100
  Current Assets4.3%10610299.0095.0090.0084.0079.0079.0073.0076.0071.0067.0062.0057.0053.0051.0055.0050.0046.0046.0061.00
    Cash Equivalents5.3%93.0088.0085.0081.0075.0070.0066.0066.0061.0064.0060.0056.0052.0046.0042.0040.0043.0037.0033.0033.0051.00
  Inventory-1.3%10.0010.0010.0010.009.008.007.007.007.006.006.006.006.006.007.007.007.006.008.008.007.00
  Net PPE2.0%11.0010.0011.0010.0010.0010.0010.0011.0011.0011.0011.0011.0011.0011.0010.0010.0011.0010.0010.0010.0010.00
  Goodwill2.0%14.0013.0014.0014.0013.0013.0013.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0013.0014.0014.0014.00
Liabilities-5.3%7.008.009.0010.0010.0010.009.0011.008.0010.009.0010.009.009.008.009.009.009.009.0013.0011.00
  Current Liabilities12.8%5.004.005.006.006.006.004.006.004.005.004.005.004.004.003.004.003.004.004.007.005.00
Shareholder's Equity3.7%12812412211811410810710910711010710510398.0095.0094.0010195.0094.0092.0089.00
  Retained Earnings2.4%138135132129126123119118115118115113111109107107111107105102100
  Additional Paid-In Capital14.0%1.001.000.000.000.000.00-1.001.001.000.000.000.00-0.00-0.00--0.000.00
Shares Outstanding0.0%4.004.004.004.004.004.004.004.004.004.004.004.004.00--------
Float-------336---286---298---327--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations4.1%5,3325,1214,9136,9155,6805,5894,8325,0464,9875,9914,6925,5335,7785,0083,6775,6745,6416,3721,6833,3604,483
  Share Based Compensation35.8%72.0053.0050.0050.0062.0038.0040.0043.0043.0041.0041.0041.0039.0049.0049.0023.0028.0029.0028.0028.0011.00
Cashflow From Investing51.6%-90.00-186-320-43.00-38.00-321-222-237-253-77.00-212-10.00-54.00-95.00-257-454-288-122-118-21,012-147
Cashflow From Financing-3.5%-1,071-1,035-1,010-1,049-920-1,032-3,55119.00-8,070-850-1,036-949-942-1,368-1,004-7,420-969-976-1,352-930-2,195
  Dividend Payments0%1,0711,0711,0701,0701,0511,0521,060-8,3491,0391,0391,0381,0191,0201,0351,0421,0291,0281,0281,0271,008
  Buy Backs--------2,495-----6,976-551--6,426398--398-1,205

UTMD Income Statement

2023-12-31
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF INCOME   
Sales, net (notes 1, 3, 9 and 11)$ 50,224$ 52,281$ 49,054
Cost of goods sold20,18620,08518,137
Gross profit30,03832,19630,917
Sales and marketing1,6851,5071,414
Research and development560493526
General and administrative11,01610,40610,097
Operating income16,77719,79018,880
Dividend and interest income3,036661166
Royalty income (note 12)202015
Other, net2561880
Income before provision for income taxes20,08920,65919,061
Provision for income taxes (note 7)3,4544,1864,273
Net income$ 16,635$ 16,473$ 14,788
Earnings per common share (basic) (note 1)$ 4.58$ 4.53$ 4.05
Earnings per common share (diluted) (note 1)$ 4.57$ 4.52$ 4.04
Other comprehensive income (loss)   
Foreign currency translation net of taxes of $0 in all periods$ 1,381$ (2,986)$ (773)
Total comprehensive income$ 18,016$ 13,487$ 14,015

UTMD Balance Sheet

2023-12-31
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash$ 92,868$ 75,052
Accounts and other receivables, net (note 2)3,3915,538
Inventories (note 2)9,5828,814
Prepaid expenses and other current assets428515
Total current assets106,26989,919
Property and equipment, net (notes 4 and 10)10,55110,224
Goodwill13,69213,354
Other intangible assets (note 2)$ 54,296$ 52,755
Operating Lease, Right-of-Use Asset, Statement of Financial PositionOther intangible assets (note 2)Other intangible assets (note 2)
Other intangible assets - accumulated amortization$ (49,350)$ (42,378)
Other intangible assets, net (note 2)4,94610,377
Total assets135,458123,874
Current liabilities  
Accounts payable7691,218
Accrued expenses (note 2)$ 3,9414,742
Operating Lease, Liability, Current, Statement of Financial PositionAccrued expenses (note 2) 
Total current liabilities$ 4,7105,960
Long term lease liability295341
Long term income tax payable (REPAT tax) (note 7)6981,256
Deferred tax liability - intangible assets1,1201,514
Deferred income taxes (note 7)322549
Total liabilities7,1459,620
Commitments and contingencies (notes 6 and 12)00
Stockholders' equity  
Common stock, $.01 par value; 50,000 shares authorized, issued 3,630 shares in 2023 and 3,628 shares in 20223636
Accumulated other comprehensive loss(10,658)(12,039)
Additional paid-in capital594251
Retained earnings138,341126,006
Total stockholders' equity128,313114,254
Total liabilities and stockholders' equity$ 135,458$ 123,874

About Utah Medical Products Inc

UTMD

Utah Medical Products Inc Frequently Asked Questions


What is the ticker symbol for Utah Medical Products Inc? What does UTMD stand for in stocks?

UTMD is the stock ticker symbol of Utah Medical Products Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Utah Medical Products Inc (UTMD)?

As of Wed Mar 27 2024, market cap of Utah Medical Products Inc is 248.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTMD stock?

You can check UTMD's fair value in chart for subscribers.

What is the fair value of UTMD stock?

You can check UTMD's fair value in chart for subscribers. The fair value of Utah Medical Products Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Utah Medical Products Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Utah Medical Products Inc a good stock to buy?

The fair value guage provides a quick view whether UTMD is over valued or under valued. Whether Utah Medical Products Inc is cheap or expensive depends on the assumptions which impact Utah Medical Products Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTMD.

What is Utah Medical Products Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, UTMD's PE ratio (Price to Earnings) is 14.72 and Price to Sales (PS) ratio is 4.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Utah Medical Products Inc's stock?

In the past 10 years, Utah Medical Products Inc has provided 0.032 (multiply by 100 for percentage) rate of return.